Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.95
-1.00-14.46%
At close: -
$6.00
0.050.91%
After Hours: Mar 28, 7:46 PM EDT
Comments
Loading...
Candel Therapeutics Analyst Ratings and Price Targets | NASDAQ:CADL | Benzinga
Candel Therapeutics Inc has a consensus price target of $15.14 based on the ratings of 7 analysts. The high is $25 issued by Canaccord Genuity on February 26, 2025. The low is $3 issued by BMO Capital on May 15, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co. on March 14, 2025, February 26, 2025, and February 26, 2025, respectively. With an average price target of $21 between HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co., there's an implied 250.06% upside for Candel Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Citigroup
B of A Securities
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Candel Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/14/2025 | Buy Now | 216.72% | HC Wainwright & Co. | Vernon Bernardino50% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 316.74% | Canaccord Genuity | John Newman45% | $20 → $25 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 216.72% | HC Wainwright & Co. | Vernon Bernardino50% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 316.74% | Citigroup | Yigal Nochomovitz54% | → $25 | Initiates | → Buy | Get Alert |
| 02/19/2025 | Buy Now | 233.39% | Canaccord Genuity | John Newman45% | → $20 | Initiates | → Buy | Get Alert |
| 02/07/2025 | Buy Now | 150.04% | B of A Securities | Alec Stranahan33% | → $15 | Initiates | → Buy | Get Alert |
| 12/18/2024 | Buy Now | 216.72% | HC Wainwright & Co. | Vernon Bernardino50% | $11 → $19 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 83.36% | HC Wainwright & Co. | Vernon Bernardino50% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2023 | Buy Now | 83.36% | HC Wainwright & Co. | Vernon Bernardino50% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 83.36% | HC Wainwright & Co. | Vernon Bernardino50% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | -49.99% | BMO Capital | Evan David Seigerman51% | $9 → $3 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | 16.69% | Credit Suisse | Judah Frommer65% | $8 → $7 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 33.36% | Credit Suisse | Judah Frommer65% | $10 → $8 | Maintains | Outperform | Get Alert |
| 12/02/2022 | Buy Now | 83.36% | HC Wainwright & Co. | Vernon Bernardino50% | → $11 | Initiates | → Buy | Get Alert |
| 03/31/2022 | Buy Now | 100.03% | BMO Capital | Evan Seigerman64% | $18 → $12 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Candel Therapeutics (CADL) stock?
The latest price target for Candel Therapeutics (NASDAQ:CADL) was reported by HC Wainwright & Co. on March 14, 2025. The analyst firm set a price target for $19.00 expecting CADL to rise to within 12 months (a possible 216.72% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Candel Therapeutics (CADL)?
The latest analyst rating for Candel Therapeutics (NASDAQ:CADL) was provided by HC Wainwright & Co., and Candel Therapeutics reiterated their buy rating.
When was the last upgrade for Candel Therapeutics (CADL)?
There is no last upgrade for Candel Therapeutics
When was the last downgrade for Candel Therapeutics (CADL)?
There is no last downgrade for Candel Therapeutics.
When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on March 14, 2025 so you should expect the next rating to be made available sometime around March 14, 2026.
Is the Analyst Rating Candel Therapeutics (CADL) correct?
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a reiterated with a price target of $19.00 to $19.00. The current price Candel Therapeutics (CADL) is trading at is $6.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.